-continued

6)

(SEQ ID NO: 18)
GRTISLYAV,

(SEQ ID NO: 19)
ISWTDSST,
and

(SEQ ID NO: 20)
AADVSIRGLQKYEYDY,
respectively; or

7)

(SEQ ID NO: 21)
TRTFSSYIM,

(SEQ ID NO: 22)
ISWSGRMT,
and

(SEQ ID NO: 23)
AADRTTAWGAPRSQYDS,
respectively.

**2**. The antibody or an antigen-binding fragment of claim **1**, wherein said antigen-binding fragment is a single-domain antibody (sdAb).

**3**. The antibody or an antigen-binding fragment of claim **1**, wherein said antibody is an IgA, IgD, IgE, IgG, or IgM.

**4**. The antibody or an antigen-binding fragment of claim **1**, wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising GFLLRSNTM (SEQ ID NO:1), IRPSGLT (SEQ ID NO:2), and HTRPPFQRDS (SEQ ID NO:3) or ATRPPFQRDS (SEQ ID NO:4), respectively.

**5**. The antibody or an antigen-binding fragment of claim **1**, wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising GRTFIAYAM (SEQ ID NO:5), ITNFAGGTT (SEQ ID NO:6), and AADRSAQTMRQVRPVLPY (SEQ ID NO:7), respectively.

**6**. The antibody or an antigen-binding fragment of claim **1**, wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising GRTFDNYVM (SEQ ID NO:8), ISGSGSIT (SEQ ID NO:9), and AAGSRRTYYREPKFYPS (SEQ ID NO:10), respectively.

**7**. The antibody or an antigen-binding fragment of claim **1**, wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising GSTFSSSSV (SEQ ID NO:11), ITSGGST (SEQ ID NO:12), and NVAGRNWVPISRYSPGPY (SEQ ID NO:13) or AVAGRNWVPISRYSPGPY (SEQ ID NO:14), respectively.

**8**. The antibody or an antigen-binding fragment of claim **1**, wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising GSIESINRM (SEQ ID NO:15), ISKGGST (SEQ ID NO:16), and AAGPVWEQF (SEQ ID NO:17), respectively.

**9**. The antibody or an antigen-binding fragment of claim **1**, wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising GRTISLYAV (SEQ ID NO:18), ISWTDSST (SEQ ID NO:19), and AADVSIRGLQKYEYDY (SEQ ID NO:20), respectively.

**10**. The antibody or an antigen-binding fragment of claim **1**, wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising TRTFSSYIM (SEQ ID NO:21), ISWSGRMT (SEQ ID NO:22), and AADRTTAWGAPRSQYDS (SEQ ID NO:23), respectively.

**11**. The antibody or an antigen-binding fragment of claim **1**, wherein said antibody or an antigen-binding fragment is humanized or partially humanized.

**12**. A compound comprising an antibody or an antigen-binding fragment according to claim **1**.

**13**. The compound of claim **12**, wherein said antibody or an antigen-binding fragment is linked to said compound via a linker sequence.

**14**. The compound of claim **13**, wherein said linker sequence is an amino acid sequence that allows for the functional linking of said compound to said antibody or an antigen-binding fragment.

**15**. The compound of claim **14**, wherein said amino acid sequence comprises about 3 to about 40 amino acids.

**16**. The compound of claims **13**, wherein said is linker sequence is $(GGGGS)_n$, wherein $n \geq 1$, or any suitable linker.

**17**. The compound of claim **12**, wherein said antibody or an antigen-binding fragment is fused to an antibody or an antigen-binding fragment, operable to bind a target epitope.

**18**. The compound of claim **12**, wherein said antibody or an antigen-binding fragment is linked to a peptide, a polypeptide, a protein, an enzyme, an antibody, an antibody fragment, or combinations thereof, wherein each of said antibody or an antigen-binding fragment and said linked peptide, polypeptide, protein, enzyme, antibody, antibody fragment, or combinations thereof are functional.

**19**. A composition comprising the compound of claim **12**, and a pharmaceutically acceptable diluent, carrier or excipient.

**20-22**. (canceled)

**23**. A method of removing a molecule from serum, comprising administering a compound according to claim **17** specific to said molecule, wherein said antibody or an antigen-binding fragment comprises CDR1, CDR2 and CDR3 comprising an amino acid sequence comprising GRTFDNYVM (SEQ ID NO:8), ISGSGSIT (SEQ ID NO:9), and AAGSRRTYYREPKFYPS (SEQ ID NO:10), respectively.

**24-26**. (canceled)

* * * * *